Core Viewpoint - The article emphasizes that cranioplasty is not merely a "patch surgery" but a complex integration of structure and morphology, where the final aesthetic outcome and long-term stability are crucial for patient satisfaction [1][3]. Group 1: Clinical Pain Points - Cranioplasty is often viewed as a "structural repair," but it involves a comprehensive challenge related to geometry, mechanics, and long-term stability [2]. - Irregular defect shapes can lead to "secondary asymmetry" during surgery, as manual adjustments to materials often fail to ensure edge continuity [2]. - Key contour areas are highly sensitive to "millimeter-level errors," which can affect tactile and visual outcomes for patients [2][4]. - Long-term stability is a core indicator of treatment efficacy, with factors like material absorption, thermal expansion, and mechanical stability influencing the durability of the reconstruction [5]. Group 2: Material System - Polyether ether ketone (PEEK) is increasingly chosen for craniomaxillofacial reconstruction due to its long-term clinical validation and alignment with cranioplasty needs [6]. - PEEK's elastic modulus closely matches that of cortical bone, allowing for a more natural edge transition and tactile experience for patients [6]. - The material is non-absorbent and corrosion-resistant, maintaining shape stability over time, which is critical for preventing "secondary changes" in appearance [6]. - PEEK exhibits excellent imaging compatibility, producing minimal artifacts in CT/MRI scans, which is vital for long-term follow-up of patients [7]. - The material possesses sufficient mechanical strength to provide predictable structural support, especially in large defects or load-bearing areas [7]. Group 3: Product Features - The newly approved localized patient-matched PEEK cranioplasty system builds on an established engineering framework, utilizing high-quality materials with over 20 years of clinical experience [9]. - The system allows for anatomical-level restoration of curvature, moving from manual sculpting to digital modeling, which resolves many shape-related issues preoperatively [11]. - The design includes a gradual thinning transition at the defect edges, enhancing tactile and aesthetic outcomes, which is difficult to achieve through manual methods [12]. - Surface roughness is controlled to balance early stability and long-term safety, ensuring a smooth interface with surrounding tissues [14]. - The layout of fixation holes is designed to meet both mechanical requirements and surgical habits, facilitating predictable surgical actions [14]. Group 4: Localization Significance - The localization of the PEEK cranioplasty system enhances accessibility to high-quality reconstruction options, allowing for clearer execution conditions in clinical settings [15]. - A defined delivery schedule supports surgical planning, making personalized implants a routine choice rather than an exception [16]. - Local design teams ensure accurate implementation of design intentions, improving interface stability and reducing risks associated with micro-movements [18]. - The production system is not a simple replication but a transfer of existing international standards, ensuring consistent quality across different regions [21].

对医疗器械公司来说，市场部的核心战场往往在会场上：新品亮相、学术教育、专家共识、渠道触达。 2026年已至，哪些大会必须参加？哪些论坛值得布局？ 思宇MedTech整理了39场医疗器械相关会议，供市场部参考（更多大会信息还在陆续发布中，我们后续会有更完整 的版本） 2026年生物医学工程、智能感知技术与医学应用国际学术会议 会议时间：2026年1月9–11日 会议地点：沈阳 第十届神经学与神经外科国际研讨会 会议时间：2026年1月9–11日 会议地点：三亚 2026年西湖心血管病临床进展研究大会 会议时间：2026年1月16–17日 会议地点：杭州 2026年3月 第三届全球生物医药大会 会议时间：2026年3月19日 会议地点：北京中关村会议中心 会议时间：2026年3月21–23日 会议地点：厦门 2026医学装备展览会 会议时间：2026年3月26–29日 会议地点： 重庆 2026年4月 CMEF 春季（中国国际医疗器械博览会） 会议时间：2026年4月9–12日 会议地点：上海 "第二十六届国际眼科学学术会议"与"第二十六届国际视光学学术会议"（COOC 2026） 会议时间：2026年4月9–1 ...

# 一个规模巨 大 、但变化缓慢的器械赛道 透析是终末期肾病患者不可替代的长期治疗方式，也是医疗器械领域中规模最大的单一治疗场景之一。但 与其市场体量并不匹配的是，该领域在治疗模式和系统效率上的变化相对有限。 在国内，透析治疗仍高度依赖中心化医疗机构，患者需长期、高频往返医院完成治疗。这一模式在保障安 全性的同时，也带来了明显的现实问题：患者时间与体力负担沉重，基层地区可及性不足，医疗机构在医 保控费和耗材集采背景下面临持续运营压力。 在此基础上，透析治疗对患者生存质量的改善空间也相对有限，使得这一领域逐渐呈现出 "刚需、高频、但 系统效率偏低" 的特征。 近日， 上海心光生物医药有限责任公司 （以下简称"心光生物"）宣布完成 数千万元A1轮融资 。本轮融资 由国际知名机构领投，老股东 兴富资本 跟投，凯乘资本担任长期财务顾问。公司表示，募集资金将主要用 于再生型腹膜透析产品的型式检验、临床试验及注册申报等关键节点。 在当前医疗器械投资更加关注 "是否解决真实系统性问题" 的背景下，心光生物所切入的透析赛道，并非高 速变化的热门领域，却长期存在结构性矛盾。本轮融资，更多体现的是资本对透析治疗模式调整可能性的 ...

中化新网讯 天津大学张晓东教授团队开发出一种新型高性能单原子生物催化材料，并将其应用于血管 支架，为心脑血管疾病的长效治疗提供了全新解决方案。相关成果已于2025年12月22日发表于国际期刊 《自然·可持续发展》。 单原子催化剂如同化学反应的"高效管家"，能快速促成关键分子的转化，具有"又快又准"的催化能力， 在能源和医疗等领域拥有广阔的应用前景。然而，如何大规模、精准地制备这类催化剂，是制约其走向 实际应用的关键难题。传统工艺难以精确控制原子分布，高温处理还容易破坏材料结构。而其他能实现 原子级精准调控的高精技术，又往往成本高昂、工艺复杂、产量有限，无法满足大规模生产和实际应用 的需要。 针对这一难题，张晓东团队独辟蹊径，提出了一种通用型单原子催化剂制备策略。他们通过机器学习与 计算机模拟，从近两万种原子结构中筛选出催化活性最高的原子;然后采用离子注入技术，将活性原 子"注入"常用医用镍钛合金的表面，从而实现单原子催化剂的高效、均匀制备。 该方法具有三大优势：规模化制备能力强，仅用数小时即可一次性做出面积达200平方厘米的催化材料; 通用性强，已成功用于制备铂-铜、钴-钒等22种不同的单原子催化剂;条件温和 ...

Core Viewpoint - Huishang Bank has successfully integrated its development with the economic growth of Anhui Province over the past 20 years, demonstrating the spirit of Huishang in the financial sector and contributing significantly to local economic development [1][3]. Group 1: Financial Contributions to Local Economy - Since its establishment, Huishang Bank has provided over 30 trillion yuan in financial support to Anhui Province during the 14th Five-Year Plan period, playing a crucial role in the province's economic transformation from an agricultural to an industrial powerhouse [3]. - The bank's total assets have exceeded 2.3 trillion yuan, with a net capital of over 170 billion yuan, while maintaining a declining trend in non-performing loans and improving risk control capabilities [3]. Group 2: Support for Innovation and Technology - Huishang Bank has issued over 210 billion yuan in technology loans, nearly 160 billion yuan in green credit, and over 170 billion yuan in inclusive microloans, demonstrating its commitment to nurturing technological innovation and supporting small and micro enterprises [4][11]. - The bank has developed a unique "Science and Technology Bank" model, focusing on providing tailored financial services to innovative enterprises, which has resulted in a significant increase in technology loan balances and the number of serviced technology companies [11][12]. Group 3: Expansion of Financial Services - Huishang Bank has expanded its personal financial services, growing its customer base from 19.5 million to 39 million in three years, indicating a strong market presence in Anhui [15]. - The bank has also launched various financial products, including "Technology Talent Loans" and "Technology R&D Loans," to support the entire lifecycle of technological enterprises [11][12]. Group 4: Strategic Goals and Future Directions - Looking ahead, Huishang Bank aims to deepen its focus on five key areas: technology finance, green finance, inclusive finance, pension finance, and digital finance, to enhance its role in optimizing the economic structure [12][16]. - The bank plans to continue innovating its financial services and products, aiming to create a comprehensive financial ecosystem that covers all aspects of lending, investment, and transaction services [16].

Core Viewpoint - The article highlights the approval of a patient-matched cranial repair implant developed by Evonik in collaboration with Tianjin Kang'er Medical Devices Co., marking a significant advancement in the application of FDM (Fused Deposition Modeling) technology in medical devices [1][2]. Group 1: Product Development and Approval - Evonik's cranial repair implant is the first personalized cranial repair prosthesis in China based on FDM technology, receiving official approval from the National Medical Products Administration (NMPA) [1]. - The product utilizes bone-integrating PEEK filament VESTAKEEP® Fusion iC4800 3DF, showcasing a breakthrough in the use of FDM technology for implantable medical devices [1]. Group 2: Material Properties and Clinical Benefits - PEEK material offers biomechanical properties that align with clinical needs, providing long-term stable protection for brain tissue [1]. - The design allows for complex porous structures and personalized anatomical shapes through 3D printing, ensuring a perfect fit for patients' cranial defects [1]. - The biocompatibility of PEEK significantly reduces surgical complexity and postoperative rejection risks, enhancing patient experience and quality of life [1]. Group 3: Industry Impact and Future Prospects - The introduction of the cranial repair implant signifies a leap into the "precision fusion" era for cranial repair in China, reflecting local advancements in PEEK material modification and application processes [2]. - Evonik's PEEK materials are positioned as key to unlocking the potential of additive manufacturing in the medical device sector, with a diverse product line that includes carbon fiber-reinforced PEEK filaments [2].

Core Viewpoint - The demand for radiotherapy positioning products in China is expected to double due to the increasing cancer population and advancements in radiotherapy technology, leading to significant market growth from 167 million yuan in 2019 to 346 million yuan by 2025, and projected to reach 411 million yuan by 2026 [1][4]. Industry Definition and Classification - Radiotherapy positioning products are essential for ensuring precise patient positioning during treatment, which is critical for targeting tumors accurately while minimizing damage to surrounding tissues [2][3]. - Key products include patient positioning bags, positioning films, and intelligent positioning systems, with positioning films being the most widely used [3]. Industry Development Status - Cancer is a major health threat, and radiotherapy is one of the three primary treatment methods, applicable in nearly all cancer treatments [3]. - The global market for radiotherapy positioning films is projected to grow from 273 million USD in 2019 to 403 million USD by 2025, with expectations of reaching 435 million USD by 2026 [4]. Industry Chain - The upstream of the industry includes raw materials such as polycaprolactone and polyurethane, while the downstream primarily consists of hospitals and radiotherapy centers, with hospitals accounting for approximately 75% of the market [4]. Policy Environment - Recent supportive policies in China, such as the "14th Five-Year" plan for large medical equipment and reforms in high-value medical consumables, are significant drivers for the development of the radiotherapy positioning products industry [6]. Competitive Landscape - The market is dominated by key players such as CIVCO Radiotherapy, Guangzhou Kelaidi Medical Equipment Co., Ltd., and Elekta, with a high concentration of industry leaders [8]. - Guangzhou Kelaidi holds a substantial market share in China, with its positioning products generating 2.23 billion yuan in revenue, accounting for 78.28% of its total revenue in 2024 [8][9]. Industry Development Trends - The industry is moving towards higher precision, intelligence, safety, and comfort in products, driven by the demand for reliable and accurate positioning in the era of "precision radiotherapy" [9].

Core Viewpoint - The "2026 Tariff Adjustment Plan" aims to scientifically adjust import provisional tax rates, optimize tariff categories, and continue implementing agreement and preferential tax rates, which will support the development of new productive forces, meet the growing needs of the people, expand high-level opening-up, and promote high-quality development [1] Group 1: Import Provisional Tax Rate Adjustments - The plan will implement lower-than-most-favored-nation tax rates on 935 items to enhance the linkage between domestic and international markets and expand the supply of quality goods [1] - Key components include reducing import tariffs on critical components and advanced materials to promote high-level technological self-reliance and the construction of a modern industrial system [2] - Tariff reductions on resource-based products like lithium-ion battery recycled black powder aim to support the green transformation of the economy and society [1][2] Group 2: Tax Category Optimization - The total number of tariff categories will be adjusted to 8,972, with new categories added for emerging products such as intelligent bionic robots and bio-aviation kerosene [3] - The adjustment will help industries and enterprises accurately grasp trade data and assess overseas market trends, facilitating the formulation of effective development strategies [3] - Continued implementation of preferential tax rates for goods from 34 trade partners and zero-tariff treatment for 43 least developed countries reflects China's commitment to deepening economic cooperation and regional integration [3]

Investment Rating - The report assigns a "Buy" rating to the company, Weigao Blood Purification [5] Core Views - Weigao Blood Purification is a leader in the domestic blood purification field, with a comprehensive product matrix that includes blood dialysis devices, dialysis machines, and peritoneal dialysis solutions. The company has shown steady performance, with projected revenue and net profit CAGR of 8.1% and 10.9% from 2020 to 2024, respectively [1][3][5] - The blood dialysis products contribute significantly to the company's revenue, with the core product, blood dialysis器, expected to account for 51.0% of total revenue in 2024 [1][5] - The blood purification industry in China is experiencing stable growth, with a market size CAGR of 5.67% from 2019 to 2023, and an expected CAGR of 21.52% from 2023 to 2027 [2][3] Summary by Relevant Sections Company Overview - Weigao Blood Purification has established itself as a leading player in the blood purification equipment sector, continuously enhancing its product offerings. The company has developed a full product line, including blood dialysis devices, dialysis machines, and peritoneal dialysis solutions [1][19] - The company has a stable and concentrated shareholding structure, with Weigao Group holding 41.75% of the shares as of June 30, 2025 [26][29] Industry Analysis - The demand for blood dialysis treatment is increasing due to the rapid growth in the number of ESRD patients and the enhancement of residents' medical payment capabilities. The number of patients receiving blood and peritoneal dialysis in China increased from 57,900 and 9,500 in 2018 to 91,700 and 15,300 in 2023, respectively [2][3] - The blood purification market is expected to expand significantly, driven by both demand and supply factors, including the continuous improvement of product offerings by domestic manufacturers [2][3] Company Advantages - Weigao Blood Purification has a strong product and research advantage, with a market share of 32.5% in blood dialysis器, 24.6% in blood dialysis machines, and 31.8% in blood dialysis管路 as of 2023, solidifying its leading position [3][12] - The company is actively expanding its overseas market presence, with overseas revenue growth of 97.5%, 54.1%, and 64.0% in 2023, 2024, and the first half of 2025, respectively [12][14] Financial Forecast and Investment Recommendations - The company is expected to achieve revenues of 36.88 billion, 40.34 billion, and 43.70 billion yuan in 2025, 2026, and 2027, respectively, with net profits of 4.52 billion, 4.99 billion, and 5.51 billion yuan [14][15] - The report highlights the potential for growth in the peritoneal dialysis liquid segment, with projected revenue growth of 48.1% in 2024 [12][15]

转自：许昌发布 《中共许昌市委关于制定许昌市国民经济和社会发展第十五个五年规划的建议》： 主动融入郑州都市圈和沿京广铁路城市发展带，构筑引领高质量发展的战略优势。落实国家重大战略、区域重大战略，融入全省"一主两副、一圈两带、 四域多点"发展格局，聚焦交通同网、产业同链、文化同兴、生态同建、服务同享，发挥特色优势，强化全域对接，进一步优化发展布局、拓展发展空 间。要协力做强郑（港）汴许主引擎，高质量建设"一带一圈两谷"，促进全方位功能对接，强化全市域整体联动。 在日前胜利闭幕的市委八届十次全会上，一个关乎城市未来走向的关键抉择被郑重写入发展蓝图：主动融入郑州都市圈，并全力对接沿京广铁路城市发展 带。 于许昌而言，从"融"出发，向"带"而行，这不仅是一次地理空间上的战略选择，更是在省委"一主两副、一圈两带、四域多点"宏大格局下，一座内陆城市 寻求能级跃升、开拓发展新优势的深刻自觉。 2025亮点 《许港产业带发展规划(2025-2035 年)》编制完成，212个重点项目前10个月完成投资740亿元，占年度投资计划的90.1%，招引亿元以上项目81个，累计到 位资金73.9亿元 芙蓉湖现代服务业创新圈聚焦科技服务、 ...